New test can detect patients' risk of harmful side effects from Alzheimer's drugs
Data on the test's performance to be presented at ADLM 2024
CHICAGO, July 31, 2024 /PRNewswire/ -- Today at ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo), researchers will present data on a novel test that predicts whether Alzheimer's patients are genetically predisposed to side effects from anti-amyloid drugs, a promising new class of Alzheimer's therapeutics. The test could improve outcomes for patients with Alzheimer's by helping to prevent instances of brain swelling or bleeding caused by these drugs.
Just last year, the anti-amyloid drug lecanemab became the first medication ever to receive Food and Drug Administration (FDA) approval for slowing the progression of Alzheimer's. More anti-amyloid drugs have received FDA approval since then, offering much-needed hope to individuals with this condition. At the same time, however, concerns have been raised about the safety of these drugs, with the FDA warning that they can cause brain swelling and/or bleeding. This side effect is known as amyloid-related imaging abnormalities (ARIA), and while it's usually mild, in rare cases, it can lead to death. The risk of ARIA is elevated in those who have particular variants of the gene APOE, which is implicated in many forms of Alzheimer's. The FDA therefore also recommends that patients undergo genetic testing before taking anti-amyloid drugs.
A team of researchers from the medical diagnostics company Revvity's Euroimmun has developed a new PCR-based test that determines if a patient has a high-risk combination of APOE variants (also known as a genotype). This method tests for all six possible APOE genotypes simultaneously, which allows for quicker processing by laboratories and ensures that patients receive results faster. To evaluate the test's performance, the researchers used it to analyze 100 blood samples from Alzheimer's patients and 10 samples from healthy blood donors. The researchers also analyzed the same samples using a CE-IVD-marked APOE test and a method known as bidirectional Sanger sequencing, then compared the results from all three methods. All the results agreed in 110 out of 110 cases, showing that the Revvity's Euroimmun test detects a patient's APOE genotype with 100% accuracy.
"There's been a lot of progress with new [anti-amyloid] drugs approved by the FDA, and as a consequence, diagnostic assays need to be updated to be able to test for the consequences of these drugs," said Dr. Maite Sabalza, senior scientific affairs manager at Revvity's Euroimmun. "There is a need to screen patients before receiving treatment, and if they are [positive for a high-risk APOE genotype], doctors can discuss the possibility of stopping or monitoring the treatment or trying something different."
The team at Revvity's Euroimmun is hopeful that their test will become part of the care Alzheimer's patients receive before taking these drugs.
"We want to help these patients," Dr. Sabalza said.
Session information
ADLM 2024 registration is free for members of the media. Reporters can register online here: https://xpressreg.net/register/adlm0824/media/landing.asp
Abstract B-236: New real-time PCR test for APOE genotyping in patients with Alzheimer's disease before anti-amyloid therapy will be presented during:
Scientific poster session
Wednesday, July 31
9:30 a.m. – 5 p.m. (presenting authors in attendance from 1:30 – 2:30 p.m.)
The session will take place in the Poster Hall on the Expo show floor of McCormick Place, Chicago.
About ADLM 2024
ADLM 2024 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo) offers 5 days packed with opportunities to learn about exciting science from July 28-August 1 in Chicago. Plenary sessions will explore the projected consequences of ending abortion protection, new HIV prevention options, lymphoma biomarkers and therapeutic targets, pharmacogenetic testing in precision health, and the need for clinical trials of laboratory tests.
At the ADLM 2024 Clinical Lab Expo, more than 900 exhibitors will fill the show floor of the McCormick Place Convention Center in Chicago, with displays of the latest diagnostic technology, including but not limited to artificial intelligence, point-of-care, and automation.
About the Association for Diagnostics & Laboratory Medicine (ADLM)
Dedicated to achieving better health through laboratory medicine, ADLM (formerly AACC) brings together more than 70,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of progressing laboratory science. Since 1948, ADLM has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit www.myadlm.org.
Christine DeLong
ADLM
Associate Director, Communications & PR
(p) 202.835.8722
[email protected]
Molly Polen
ADLM
Senior Director, Communications & PR
(p) 202.420.7612
(c) 703.598.0472
[email protected]
SOURCE Association for Diagnostics & Laboratory Medicine (ADLM)
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article